BEAM News and Press, Beam Therapeutics Inc.

2026-06-03 09:35:45 ET BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript Bausch + Lomb Corpo...

2026-06-02 13:50:48 ET More on CRISPR Therapeutics, Intellia Therapeutics Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight These Are The Upcoming Catalysts For Crispr Therapeutics Stock Intellia Therapeutics, Inc. (NTLA) Presents at Bank...

2026-05-28 12:41:35 ET Issued on behalf of Avaí Bio, Inc. As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α...

2026-05-25 20:55:00 ET The gene-editing niche of the biotech industry is gaining momentum, as various companies focused on these techniques -- which allow scientists to alter patients' DNA to treat some diseases -- have made significant clinical progress over the past decade or so. Two no...

2026-05-25 13:37:05 ET Beam Therapeutics Inc. (BEAM) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 10:30 AM EDT... Read the full article on Seeking Alpha For further details see: Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Health...

2026-05-21 17:40:46 ET Shares of Crispr Therapeutics AG ( CRSP ), the Zug, Switzerland-based biotechnology company, have been stuck within a trading range for about four and a half years now. Investor enthusiasm around the Casgevy launch – a one-time CRISPR/Cas-9 technolo...

2026-05-21 08:15:07 ET Patrick Trucchio from H.C. Wainwright issued a price target of $80.00 for BEAM on 2026-05-21 10:39:00. The adjusted price target was set to $80.00. At the time of the announcement, BEAM was trading at $27.11. The overall price target consensus is a...

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency ...

2026-05-18 14:25:44 ET On May 15, 2026, ADAR1 Capital Management disclosed a new position in Beam Therapeutics (NASDAQ:BEAM) , acquiring 1,446,375 shares in an estimated $40.13 million trade based on quarterly average pricing. According to a Securities and Exchange Commission ...

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C. , May 13, 2026...